Showing results (591-600 of 617) with videos related to

Sort By:
Pageof 62
Gynecologic Oncology|August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experienceKate E Oliver, William E Brady, Michael Birrer, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Clinical Proteomics|October 6, 2025
Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancersChristopher M Tarney, Paulette Mhawech-Fauceglia, Jonathan D Ogata, et al.
Gynecologic Oncology|April 11, 2012
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancerSiqing Fu, Bryan T Hennessy, Chaan S Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2024
Clinical and Genomic Landscape of RAS Mutations in Gynecologic CancersJi Son, Yingao Zhang, Heather Lin, et al.
Journal of Translational Medicine|December 17, 2022
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivorsKwong-Kwok Wong, Nicholas W Bateman, Chun Wai Ng, et al.
Gynecologic Oncology|May 6, 2023
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary studyTiffany Y Sia, William P Tew, Christopher Purdy, et al.
Lancet (London, England)|February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trialDavid M Gershenson, Austin Miller, William E Brady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
Pageof 62